Follow Fast Money Trades Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
A couple weeks ago, I showed you a market-crushing leader that defines high-tech wealth.
The fact is that Proofpoint Inc. (NASDAQ: PFPT) is a great way to play the field of anti-phishing cyber security, a major growth field.
But don't take my word for it. None other than the FBI says these kinds of intrusions cost the American public $12.5 billion in financial damages in the 55 months ended May 2018.
And during that period, early Proofpoint's stock totally cleaned up. From Nov. 12, 2012, when it closed at $10.22 through its most recent closing high of $130.14 on Oct. 15, 2019, PFPT made 1,173.4%.
Along the way, the stock beat the benchmark S&P 500 by a stunning 902.5%.
Even better, just $25,000 invested in Proofpoint would have turned into $313,350 in only seven years.
But don't worry. I still see plenty of upside ahead. In as little as three years, that original $25,000 will be worth a conservatively estimated $1.27 million.
Let me show you why it's still not too late to get in on all the action...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.